KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Short term Debt (2016 - 2025)

Sarepta Therapeutics has reported Short term Debt over the past 11 years, most recently at $36.0 million for Q3 2025.

  • Quarterly results put Short term Debt at $36.0 million for Q3 2025, down 60.7% from a year ago — trailing twelve months through Sep 2025 was $36.0 million (down 60.7% YoY), and the annual figure for FY2023 was $105.5 million, changed.
  • Short term Debt for Q3 2025 was $36.0 million at Sarepta Therapeutics, down from $91.6 million in the prior quarter.
  • Over the last five years, Short term Debt for SRPT hit a ceiling of $105.6 million in Q1 2024 and a floor of $36.0 million in Q3 2025.
  • Median Short term Debt over the past 3 years was $91.6 million (2024), compared with a mean of $86.0 million.
  • Peak annual rise in Short term Debt hit 60.7% in 2025, while the deepest fall reached 60.7% in 2025.
  • Sarepta Therapeutics' Short term Debt stood at $105.5 million in 2023, then dropped by 13.17% to $91.6 million in 2024, then crashed by 60.7% to $36.0 million in 2025.
  • The last three reported values for Short term Debt were $36.0 million (Q3 2025), $91.6 million (Q3 2024), and $91.5 million (Q2 2024) per Business Quant data.